Search Results - "Tanaka, Yoshiya"

State‐of‐the‐art treatment of systemic lupus erythematosus by Tanaka, Yoshiya

“…As glucocorticoids and immunosuppressive drugs are non‐specific therapeutic agents that cause many adverse reactions, the development of biologicals aiming to…”
Get full text

Clinical immunity in bone and joints by Tanaka, Yoshiya

“…The immune system and bone metabolism influence each other. An imbalance in the immune system, resulting in inflammatory stimuli may induce an imbalance in…”
Get full text

A review of upadacitinib in rheumatoid arthritis by Tanaka, Yoshiya

“…Rheumatoid arthritis (RA) is a chronic inflammatory disease primarily affecting the joints and is associated with significant levels of disability and reduced…”
Get full text

Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside by Tanaka, Yoshiya

“…Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by synovial inflammation and joint destruction. However, the combined use of synthetic…”
Get full text

RANKL as a therapeutic target of rheumatoid arthritis by Tanaka, Sakae, Tanaka, Yoshiya

“…Rheumatoid arthritis (RA) is an inflammatory disorder characterized by progressive joint destruction. Recent studies have demonstrated that osteoclasts are…”
Get full text

Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? by Tanaka, Yoshiya

“…Biological agents targeting tumour necrosis factor (TNF) have revolutionised the treatment of rheumatoid arthritis (RA) and clinical remission has become a…”
Get more information

Current concepts in the management of rheumatoid arthritis by Tanaka, Yoshiya

“…Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction that causes significant morbidity and mortality…”
Get full text

Trial of Anifrolumab in Active Systemic Lupus Erythematosus by Morand, Eric F, Furie, Richard, Tanaka, Yoshiya, Bruce, Ian N, Askanase, Anca D, Richez, Christophe, Bae, Sang-Cheol, Brohawn, Philip Z, Pineda, Lilia, Berglind, Anna, Tummala, Raj

“…A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite primary end point of lupus scores…”
Get full text

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach by Tanaka, Yoshiya, Luo, Yiming, O’Shea, John J., Nakayamada, Shingo

“…The four Janus kinase (JAK) proteins and seven signal transducer and activator of transcription (STAT) transcription factors mediate intracellular signal…”
Get full text

Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials by Tanaka, Yoshiya, Tummala, Raj

“…Chronic activation of the type I interferon (IFN) pathway plays a critical role in systemic lupus erythematosus (SLE) pathogenesis. Anifrolumab is a human…”
Get full text

A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia by Tanaka, Yoshiya

“…In inflamed tissue, immune cells are accumulated, and various intercellular signals are involved in the pathogenesis. Janus kinases (JAKs) are typical tyrosine…”
Get full text

Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system by Tanaka, Yoshiya, Ohira, Takeshi

“…•RA patients may have primary disease-related or glucocorticoid-induced osteoporosis.•Current RA treatments do not simultaneously treat bone erosion and…”
Get full text

What are the hot topics in Japanese rheumatology? Go above and beyond by Tanaka, Yoshiya

“…Japanese rheumatology and immunology have contributed to progress in the field and advancement of rheumatology, including postmarketing surveillance,…”
Get full text

Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis by Tanaka, Yoshiya

“…PURPOSE OF REVIEWBiologics targeting tumor necrosis factor (TNF) has revolutionized the treatment of rheumatoid arthritis (RA) and clinical remission becomes a…”
Get full text

Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry by Ochi, Sae, Sonomoto, Koshiro, Nakayamada, Shingo, Tanaka, Yoshiya

“…Treatment of difficult-to-treat rheumatoid arthritis (D2T RA) is one of the greatest unmet needs in rheumatology. This study aims to find out preferable…”
Get full text

Why remission is not enough: underlying disease mechanisms in RA that prevent cure by Schett, Georg, Tanaka, Yoshiya, Isaacs, John D.

“…Cure is the aspirational aim for the treatment of all diseases, including chronic inflammatory conditions such as rheumatoid arthritis (RA); however, it has…”
Get full text

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis by Taylor, Peter C, Keystone, Edward C, van der Heijde, Désirée, Weinblatt, Michael E, del Carmen Morales, Liliana, Reyes Gonzaga, Jaime, Yakushin, Sergey, Ishii, Taeko, Emoto, Kahaku, Beattie, Scott, Arora, Vipin, Gaich, Carol, Rooney, Terence, Schlichting, Douglas, Macias, William L, de Bono, Stephanie, Tanaka, Yoshiya

“…In a phase 3 randomized trial of 1307 patients with rheumatoid arthritis receiving background methotrexate, the oral JAK1 and JAK2 inhibitor baricitinib showed…”
Get full text

Genome-oriented treatment strategies for autoimmune diseases by Tanaka, Yoshiya

Get full text

Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials by Tanaka, Yoshiya, Izutsu, Hiroyuki

“…The treatment of rheumatoid arthritis (RA), a chronic, systemic, autoimmune disease, has been greatly advanced by the introduction of biologic…”
Get more information

Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions by Schett, Georg, Emery, Paul, Tanaka, Yoshiya, Burmester, Gerd, Pisetsky, David S, Naredo, Esperanza, Fautrel, Bruno, van Vollenhoven, Ronald

“…Improvements in the control of inflammation in rheumatoid arthritis (RA) by conventional synthetic and biologic disease-modifying antirheumatic drugs (DMARDs)…”
Get more information